The advent of large scale, high-throughput genomic screening has introduced a wide range of tests for diagnostic purposes. Prominent among them are tests using microRNA (miRNA) expression levels. Genomics and proteomics now provide expression levels of hundreds of miRNAs at a time. However, for actual diagnostic tools to become reality requires the simultaneous development of methods to interpret the large amounts of miRNA expression data that can be generated from a single patient sample. Because these data are in numeric form, quantitative methods must be developed. Statistics such as p-values and log fold change give some insight, but the diagnostic effectiveness of each miRNA test must first be evaluated. Here, the author has developed a traditional, sensitivity-and specificity-based algorithm, as well as a modern machine learning algorithm, and evaluated their diagnostic potential for lung cancer against a publicly available database. The findings suggest that the machine learning algorithm achieves higher accuracy (97% for cancerous and 73% for normal samples), in addition to providing confidence intervals that could provide valuable diagnostic support. The machine learning algorithm also has significant potential for expansion to more complex diagnoses of lung cancer sub-types, to other cancers, as well diseases beyond cancer. Both algorithms are available on the Github repo: https://github.com/neerja-g/machine-learning-miRNA .
1.

Introduction
Lung Cancer is the leading cause of death among both male and female cancer patients, accounting for 25% of all cancer deaths [1] . There are over 430,000 Americans living today who have been diagnosed with lung cancer at some time. While the popular belief is that lung cancer is caused by the inhalation of carcinogens due to smoking, 20-30% of patients diagnosed with lung cancer have never smoked, leading researchers to believe that smoking is not the root cause of lung cancer. Additionally, not much is known about the genetic basis of this disease.
Although significant advances have been made to treat and detect lung cancer, often, it is not detected until it is in an advanced stage, and is nearly untreatable. microRNAs (miRNAs) are small RNA (Ribose Nucleic Acid) molecules that do not code proteins. Instead, they may "silence" the activity of certain RNAs, and regulate the actions of certain genes. Because of these functions, miRNA biomarkers have recently been used as a means to detect and predict diseases by using expression levels derived from tissue samples such as tumors. However, this method is often invasive, involves long recovery periods and can potentially lead to complications if performed incorrectly. In contrast, biomarkers derived from blood, urine, or saliva can serve the same purpose as other tissue biomarkers, while being significantly less invasive than their tissue. These advantages have made miRNA testing for lung cancer and other diseases more viable as a diagnostic approach. In parallel, there is now a growing number of studies that seek to develop techniques to interpret miRNA readouts.
Because 100s or even 1000s of miRNAs can be tested for, the pROCessing of these results has fueled an increase in high throughput methods using bioengineering principles, prominent among them being lab-on-chip techniques. They have been complemented by quantitative methods in computational biology that use a range of statistical and mathematical algorithms. An early example was a study by Baldi & Long [2] , who applied a Bayesian statistical analysis to DNA microarrays, which was found to be more effective than the simple t-test or fold methods. Lu et al. [3] conducted a study that used a novel, flow cytometric miRNA expression profiling technique to analyze miRNAs from samples, including cancerous ones. The expression levels reflected the development and differentiation of the tumors, and an overall downregulation of miRNAs was observed when compared to healthy tissue samples. Chin et al. [4] identified a single-nucleotide polymorphism (SNP) in an let-7 miRNA complementary site of the KRAS gene's 3' untranslated region (UTR) that increased risk for a variant called non-small cell lung cancer. Exosomal miRNA biomarkers from both cancer and non-cancer samples have been used as a benchmark to create a screening test that would indicate whether an individual had lung cancer [5] . MicroRNA expression levels have also been used in conjunction with CT scans as another method to diagnose lung cancer [6] . The study found that miRNA expression levels from healthy lung tissue showed key associations with clinical presentation, indicating the influence of a conducive microenvironment for developing tumors. Bianchi et al. [7] developed a diagnostic test derived from the detection of 34 miRNAs in serum that allowed them to identify still-early non-small cell lung carcinomas in asymptomatic patients who were high-risk individuals for lung cancer.
This study seeks to add to the body of research that develops computational genomic approaches to efficiently screen for lung cancer. It is based on expression levels of miRNAs in a large dataset obtained from the Gene Expression Omnibus (GEO) [8] . First, the sensitivity and specificity [9, 10] of the miRNAs in the dataset are examined to determine their suitability as diagnostic tests for lung cancer. Subsequently, a machine learning model is developed [11, 12] and trained on this dataset, as an alternate computational diagnostic tool. The two algorithms thus developed can be applied in future to individualized patient samples that have been tested for expression levels of the same array of miRNAs as in the dataset used here, with the goal of predicting the probability that a given patient sample is cancerous. They can also be extended to diagnosis of more complex sub-types of lung cancer, to other cancers and other diseases. The dataset used in this study was obtained from GEO [8] , which provides RNA expression data for many different diseases. The specific dataset used here is GSE61741, and provided miRNA expression levels for 1049 patients, 73 of whom were known to have lung cancer, and 94 of whom were healthy. One possible role of miRNAs in the cancerous samples could be the downregulation of apoptotic signaling pathways (Figure 1) . The other 882 patients had varying diseases, from glaucoma to sarcoidosis. Statistical analysis was performed on these two sample groups using GEO2R, GEO's integrated statistical analysis tool, and the p-value, adjusted p-value, t-value, B, and log fold change of all 848 miRNA samples were calculated. All algorithms were written and run as scripts in the freely available statistical software package, R.
Methods
Data analysis for sensitivity and specificity
One way to evaluate the usefulness of any test is to calculate its sensitivity and specificity. Sensitivity can be defined as the proportion of true positives in a test, that is, the proportion of tests that actually detected a disease state (test positives) relative to the total number of samples that are confirmed with the disease state (sample positives). Specificity is the proportion of tests that correctly detected a disease-free state (test negatives) relative to the total number of samples that were confirmed to be free of the disease (sample negatives). See Scholkopf et al. [9] and Gentleman et al. [10] for more extensive discussions of these statistical measures, and Davuluri et al. [13] or Mathe et al. [14] for applications in computational biology.
In the example of With the sensitivity and specificity of each miRNA determined by coding this algorithm in R, all 848 miRNAs were applied to the test data in the matrix G 2 to evaluate their effectiveness at identifying cancerous (positive) and normal (negative) samples. See the Results section.
A supervised machine learning binary classification algorithm to identify cancer
Machine Learning algorithms constitute a class of Artificial Intelligence methods that enable the learning of models and decision making with minimal intervention from the scientist [15] . They have proved particularly powerful for complex problems in science and engineering, as well as in marketing, image, text and speech recognition [16] , predictions in sports, business and politics [11, 12] and even autonomous driving [17] . They are very effective on problems with large datasets, which may otherwise be difficult to gain insight to. Machine learning algorithms include regression fits (developing a mathematical model to fit data) or classification methods (grouping data). Since, in this study, it is of interest to separate samples into cancerous and normal classes, binary classification methods are appropriate. The training dataset, with samples already labelled as cancerous and normal, can be used to "train" the binary classification algorithm, and the approach can be further described as "supervised learning". Trained, supervised machine learning classification algorithms can be applied to test datasets to make predictions. Machine learning algorithms are increasingly being used in computational biology.
For some examples see Brown et al. [18] and Ben-Hur et al. [19] . Here, a supervised machine learning binary classification algorithm is trained and applied to prediction of cancer in the test dataset. It was developed by following the Massively Open Online Course "Machine Learning" offered by Prof. Andrew Ng of Stanford University on the Coursera platform [20] .
In machine learning, each sample, whether in the training or test dataset is described by a fixed number of features collected into a feature vector, say X j for each sample j . For the dataset obtained from GEO, the individual miRNA expression levels are the features for each sample. 
Results
The results of training the Threshold Algorithm and the supervised machine learning binary classification algorithm are discussed below, as well as their performance on the test data.
Calibration of the Sensitivity/Specificity Algorithm for determining and testing results
The Receiver Operating Characteristic curve (ROC) shows the variation in the true positive rate, or TPR (also the sensitivity) versus the false positive rate or FPR (also equal to 1 -specificity) as the threshold is varied over the range of the values in the test [21] . and specificities were chosen for each training set, and compared against the corresponding test set (the dataset minus training set) to determine the effectiveness of the corresponding miRNAs as tests for detecting cancer, and for ruling it out. Tables 2 and 3 present the results for the case where the training set contained 10% of samples in the data set, and Tables 4 and 5 present results for the case where the training set contained 70% of the samples in the dataset The data in Tables 2-5 show that the highest sensitivity miRNAs obtained from each training set have high true positive rates (TPRs) and the corresponding highest specificity miRNAs have high true negative rates (TNRs). However the high sensitivity miRNAs also have high false positive rates (FPRs), while the high specificity miRNAs have high false negative rates (FNRs). Recall that a high sensitivity test is meant to be useful to identify normal (negative) samples (Section 2.1). However, the high FPRs of the high sensitivity miRNAs in Tables 2 and 4 compromises their effectiveness as diagnostic tests for identifying normal (negative) samples.
Similarly, a high specificity test is meant to be useful to confirm diseased (positive) samples (Section 2.1). However the high FNRs of the high specificity miRNAs compromises their effectiveness as diagnostic tests for confirming diseased (positive samples). In this context only miRNA hsa-let-7d* in Table 3 (Column 1) is a somewhat viable test for confirming disease because it has a high TNR and low FNR. No other miRNA is comparable as a test to confirm disease, and no miRNA meets the bar for ruling out normal (negative) cases.
Tables 2--5 also show that increasing the training set does not markedly improve the reliability of the miRNAs as diagnostic tests using sensitivity and specificity. The results in Table 5 are poorer than in Table 3 even though the data in Table 5 is seven times as large as in Table 3 . This is surprising; a well-designed test should improve in its predictivity with larger training sets.
Training the machine learning algorithm and test results
The supervised binary classification machine learning algorithm was trained with learning rate and regularization parameter . Recall that allows the algorithm . The red curve in Figure 5 shows the average probability of a positive, or cancerous outcome for the samples identified as being positive or cancerous versus the training data set size. This probability reaches close to 1 for the larger training sets. The green curve is, conversely, the average probability of a positive, or cancerous outcome for the samples identified as being negative/normal versus the training data set size. This probability reaches a low of 0.03 for the larger training sets. These are important measures of the confidence in the predictions (accuracy) presented in Figure 4 , and can prove useful in actual clinical diagnoses. A higher probability that a sample identified as being cancerous is indeed cancerous is an important measure to gauge reliability of the test. The same can be said if there is a lower probability that a 
Discussion
The advent of genomics has brought many advances in medicine and biotechnology. The most exciting of these are in the diagnosis and treatment of diseases. Given the complexities of cancer [22] it is not surprising that there is considerable interest in applying genomics to its diagnosis and treatment. This study has investigated the role of miRNAs in cancer diagnosis. Large scale miRNA sequencing [23] has made it possible to use 100s of them as distinct tests for diseased and normal states. However, this also presents a "big data" problem , where the volume of information available can overwhelm the ability to use it in a meaningful manner. This is where computational biology, and specifically, computational genomics, becomes relevant. Statistical, data-driven algorithms can be used to analyze the genomic data and make predictions that mere observation of 100s of miRNA array tests cannot discern. Here, the sensitivity and specificity, which are traditional statistical measures, have been compared against a modern machine learning algorithm for identifying cancerous and normal samples using miRNA expression data.
The data set in this study included a large number of miRNAs (848), and a moderate number of samples (167), which were separated into training and test sets for the calibration and validation of the algorithms. It is notable (Tables 2--5) that the high sensitivity miRNAs had high false positive rates (FPRs) on the test data, compromising their effectiveness as tests for identifying normal samples (Tables 2 and 4) . Similarly, the high specificity miRNAs had high false negative rates (FNRs) on the test data, compromising their effectiveness as tests for identifying cancerous samples (Tables 3 and 5) .
These results, while seeming to undermine sensitivity and specificity as statistical measures in computational genomics-based diagnostics, should be approached with caution.
They have been obtained with a single data set, which while not small, may have unknown biases in it. It is therefore necessary to apply the sensitivity/specificity tests to more data sets of greater population diversity before reaching definitive conclusions on their effectiveness.
The notable features of the supervised binary classification machine learning algorithm in Section 3.2 are its high accuracies at identifying both cancerous (positive) and normal (negative) samples in the test sets (Figure 4) , and the accompanying probabilities of correctness of these predictions ( Figure 5 ). Importantly, this algorithm, trained on the identical datasets as the sensitivity/specificity tests, shows clear improvements in its accuracy at predicting both cancerous and normal samples, and in the probabilities of correctness of these predictions, with increasing training set size. This trend is expected of high performance prediction methods.
As with the sensitivity and specificity measures, the machine learning algorithm also could be trained and tested against larger and more diverse data sets. Given the encouraging preliminary results, it may be expected that it will similarly perform well.
Placing this work in context
The present work adds to the growing literature on computational genomics, especially on machine learning approaches for miRNA-based diagnosis of cancer. A small collection of these studies is available in Refs 24-29. The studies in Refs 24, 25, 26 and 29 used a different machine learning algorithm: a support vector machine (SVM). The others were the iterative signature algorithm [27] and a Naïve Bayesian classifier [28] . These machine learning algorithms were applied to study breast, urothelial, colorectal and lung cancers. The sample sizes ranged from 36 to 141 [24, 25, 29] , and the numbers of miRNAs from 12 [25, 27] to 866 [29] .
Relative to the above works, the present study used a training sample sizes that were comparable: 16 to 117, with corresponding test datasets ranging from 151 down to 50, respectively. The high probabilities of correctness of the results on the test sets have already been discussed. The feature vector size, i.e., the number of miRNAs in the present study compares with the largest in the above studies [29] , which also was a GSE dataset. It is likely that the high accuracies gained are related to this large feature vector. The binary classification algorithm here maybe considered somewhat more elementary than an SVM, but its simplicity could be an advantage in encouraging its use by others, which is a goal of future work (Section 4.2).
Future work
To extend this study, both algorithms will be challenged with larger and more diverse data sets from the GEO repository. This study has potential for broad impact in medicine, because both algorithms developed and tested here can be applied to many medical conditions that allow a binary classification into diseased and normal states. They therefore serve as quite general models for computational genomics-based diagnostic tests. The R codes for both algorithms are well-commented, allowing even a beginning user of R to easily modify and apply them to other data sets, or even to studies of different conditions. A more complex condition involving multiple classes would require a different, multi-class classification machine learning algorithm, which is a planned future extension of this work. This could, for instance, be trained against an miRNA array data set with small cell lung cancer, non-small cell lung cancer and lung carcinoid tumor samples and then against sub-types of other cancers and non-cancer diseases.
Another direction of investigation will extend the machine learning algorithms and codes to select the most effective feature vectors (miRNAs). This could also suggest which miRNAs have similarity of action. All R scripts for both algorithms are available on the GitHub repository https://github.com/neerja-g/machine-learning-miRNA under the LGPL 3.0 license.
Ultimately, the goal is to bring such computational genomics into the clinical setting, where decisions could be reached with greater confidence, given the very quantitative measures of accuracy and probability that the machine learning algorithms provide. Even further, there exists the possibility of alerting a currently healthy individual to the odds of developing a condition in the future. This of course, would also require longer term studies on the change in performance of the algorithms in terms of outcomes, accuracies, and probabilities over many years as the data from the same set of patients changes with their state of health.
